Influenza vaccines: from whole virus preparations to recombinant protein technology (Q38160083)

30 August 2017

Influenza vaccines: from whole virus preparations to recombinant protein technology (English)

1 reference

30 August 2017

1 reference

Victor C Huber

1

1 reference

30 August 2017

1 January 2014

1 reference

Expert Review of Vaccines

30 August 2017

1 reference

30 August 2017

13

1 reference

30 August 2017

31-42

1 reference

30 August 2017

1

1 reference

Preventing and treating influenza

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Mapping of Antigenic Changes in the Haemagglutinin of Hong Kong Influenza (H3N2) Strains using a Large Panel of Monoclonal Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The annual production cycle for influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus genome consists of eight distinct RNA species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza A viruses: new research developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus hemagglutinin cleavage into HA1, HA2: no laughing matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Reactions of antibodies with surface antigens of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The neuraminidase of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A distinct lineage of influenza A virus from bats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Intestinal influenza: Replication and characterization of influenza viruses in ducks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Transmission of avian influenza viruses to and between humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Sialic acid species as a determinant of the host range of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Airborne transmission of influenza A/H5N1 virus between ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Source for influenza pandemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

On the origin of the human influenza virus subtypes H2N2 and H3N2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Are we ready for pandemic influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Reassortment of pandemic H1N1/2009 influenza A virus in swine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Molecular aspects of the epidemiology of virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza pandemics in Singapore, a tropical, globally connected city

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza pandemics of the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Trends and epidemics of influenza and pneumonia: 1918-1951

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Asian influenza surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Studies of two kinds of virus particles which comprise influenza A2 virus strains. III. Morphological characteristics: independence to morphological and functional traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Haemagglutinin Relationships of Hong Kong(H3) and Asian(H2) Influenza Strains Delineated by Antigen-Specific Recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Identification and Preliminary Antigenic Analysis of Swine Influenza-Like Viruses Isolated during an Influenza Outbreak at Fort Dix, New Jersey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977-1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 201

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The 2009 A (H1N1) influenza virus pandemic: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

An influenza A H1N1 virus revival - pandemic H1N1/09 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Avian influenza A virus (H7N7) epidemic in The Netherlands in 2003: course of the epidemic and effectiveness of control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Human infection with a novel avian-origin influenza A (H7N9) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Human infection with influenza H9N2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

H5N1 influenza viruses: outbreaks and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Bacterial pathogens and death during the 1918 influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A Virus Obtained from Influenza Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A NEW TYPE OF VIRUS FROM EPIDEMIC INFLUENZA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Protective Effect of Vaccination Against Induced Influenza A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Importance of antigenic composition of influenza virus vaccine in protecting against the natural disease; observations during the winter of 1947-1948.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. II. Immunization of children with influenza A/New Jersey/X-53 virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Reactogenicity and Immunogenicity of Bivalent Influenza A and Monovalent Influenza B Virus Vaccines in High-Risk Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Clinical Trials with Inactivated Monovalent (A/New Jersey/76) and Bivalent (A/New Jersey /76-A/Victoria/75) Influenza Vaccines in Los Angeles Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The 2009-2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Adaptation and Growth Characteristics of Influenza Virus at 25° C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

DISSOCIATION OF HEMAGGLUTINATING AND ANTIBODY-MEASURING CAPACITIES OF INFLUENZA VIRUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

IMMUNOLOGICAL STUDIES WITH THE VIRUS OF INFLUENZA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Eight-plasmid system for rapid generation of influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Viral reassortment as an information exchange between viral segments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The development of vaccine viruses against pandemic A(H1N1) influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Rescue of influenza B virus from eight plasmids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Avian influenza virus (H5N1): a threat to human health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safe administration of influenza vaccine to patients with egg allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The use of beta-propiolactone for the preparation of virus vaccines. II. Antigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Novel viral vectored vaccines for the prevention of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Recombinant protein vaccines produced in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A fast track influenza virus vaccine produced in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Production of a novel influenza vaccine using insect cells: protection against drifted strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The rationale for quadrivalent influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Protection of mice with recombinant influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Preparation and characterization of a purified influenza virus neuraminidase vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Antibody response to the M2 protein of influenza A virus expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers: A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Correlates of vaccine protection from influenza and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.852476

10.1586/14760584.2014.852476

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24192014